Universität zu Köln

Agosta, Federica ORCID: 0000-0003-3121-4979, Altomare, Daniele ORCID: 0000-0003-1905-8993, Festari, Cristina ORCID: 0000-0003-3597-5097, Orini, Stefania, Gandolfo, Federica, Boccardi, Marina ORCID: 0000-0001-6744-8246, Arbizu, Javier ORCID: 0000-0002-8370-5510, Bouwman, Femke, Drzezga, Alexander, Nestor, Peter ORCID: 0000-0002-5860-5921, Nobili, Flavio ORCID: 0000-0001-9811-0897, Walker, Zuzana ORCID: 0000-0001-7346-8200 and Pagani, Marco (2018). Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. Eur. J. Nucl. Med. Mol. Imaging, 45 (9). S. 1546 - 1557. NEW YORK: SPRINGER. ISSN 1619-7089

Full text not available from this repository.

Abstract

To evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosis of amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington's disease (HD); and detecting metabolic changes related to cognitive impairment in (iii) ALS and (iv) HD patients. Four comprehensive literature searches were conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted using the Delphi method on these four diagnostic scenarios. The availability of evidence was good for FDG-PET utility to support the diagnosis of ALS, poor for identifying presymptomatic subjects carrying HD mutation who will convert to HD, and lacking for identifying cognitive-related metabolic changes in both ALS and HD. After the Delphi consensual procedure, the panel did not support the clinical use of FDG-PET for any of the four scenarios. Relative to other neurodegenerative diseases, the clinical use of FDG-PET in ALS and HD is still in its infancy. Once validated by disease-control studies, FDG-PET might represent a potentially useful biomarker for ALS diagnosis. FDG-PET is presently not justified as a routine investigation to predict conversion to HD, nor to detect evidence of brain dysfunction justifying cognitive decline in ALS and HD.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Agosta, Federica UNSPECIFIED orcid.org/0000-0003-3121-4979 UNSPECIFIED Altomare, Daniele UNSPECIFIED orcid.org/0000-0003-1905-8993 UNSPECIFIED Festari, Cristina UNSPECIFIED orcid.org/0000-0003-3597-5097 UNSPECIFIED Orini, Stefania UNSPECIFIED UNSPECIFIED UNSPECIFIED Gandolfo, Federica UNSPECIFIED UNSPECIFIED UNSPECIFIED Boccardi, Marina UNSPECIFIED orcid.org/0000-0001-6744-8246 UNSPECIFIED Arbizu, Javier UNSPECIFIED orcid.org/0000-0002-8370-5510 UNSPECIFIED Bouwman, Femke UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Nestor, Peter UNSPECIFIED orcid.org/0000-0002-5860-5921 UNSPECIFIED Nobili, Flavio UNSPECIFIED orcid.org/0000-0001-9811-0897 UNSPECIFIED Walker, Zuzana UNSPECIFIED orcid.org/0000-0001-7346-8200 UNSPECIFIED Pagani, Marco UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-180366
DOI:	10.1007/s00259-018-4033-0
Journal or Publication Title:	Eur. J. Nucl. Med. Mol. Imaging
Volume:	45
Number:	9
Page Range:	S. 1546 - 1557
Date:	2018
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1619-7089
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CEREBRAL GLUCOSE-UTILIZATION; POSITRON-EMISSION-TOMOGRAPHY; FRONTOTEMPORAL DEMENTIA; PROGRESSIVE DEMENTIA; SCAN INVESTIGATIONS; METABOLIC NETWORK; OXYGEN-METABOLISM; RECEPTOR-BINDING; EARLY-DIAGNOSIS; BLOOD-FLOW Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/18036